{"id":71527,"date":"2026-08-03T14:00:02","date_gmt":"2026-08-03T06:00:02","guid":{"rendered":"https:\/\/flcube.com\/?p=71527"},"modified":"2026-08-03T14:00:03","modified_gmt":"2026-08-03T06:00:03","slug":"roches-vabysmo-wins-nmpa-approval-for-retinal-diseases-in-china-market-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=71527","title":{"rendered":"Roche&#8217;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted formal approval for the <strong>single-dose pre-filled syringe formulation of Vabysmo (faricimab)<\/strong> to treat <strong>neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Approval Type<\/strong><\/td><td>Full marketing authorization<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Vabysmo (faricimab) pre-filled syringe (PFS)<\/td><\/tr><tr><td><strong>Indications<\/strong><\/td><td>nAMD, DME, and RVO-related macular edema<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>31 Jul 2026<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>Commercial launch expected Q3 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Faricimab \u2013 the world\u2019s first <strong>bispecific antibody<\/strong> engineered specifically for intraocular injection<\/li>\n\n\n\n<li><strong>Dual Targets:<\/strong> Simultaneously inhibits <strong>vascular endothelial growth factor A (VEGF-A)<\/strong> and <strong>angiopoietin-2 (Ang-2)<\/strong><\/li>\n\n\n\n<li><strong>Innovation:<\/strong> Addresses both abnormal blood vessel growth and vascular destabilization, reducing leakage, inflammation, and fibrosis more comprehensively than single-pathway inhibitors<\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Enables extended treatment intervals while maintaining visual acuity, potentially reducing treatment burden for patients<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-global-phase-iii-program\" class=\"wp-block-heading\">Clinical Evidence \u2013 Global Phase III Program<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Indication<\/th><th>Key Outcome<\/th><\/tr><\/thead><tbody><tr><td><strong>TENAYA\/LUCERNE<\/strong><\/td><td>nAMD<\/td><td>44\u201345% of patients maintained vision with dosing every 16 weeks vs. every 8 weeks for aflibercept<\/td><\/tr><tr><td><strong>YOSEMITE\/RHINE<\/strong><\/td><td>DME<\/td><td>Superior reduction in central subfield thickness vs. aflibercept at week 52<\/td><\/tr><tr><td><strong>BALATON\/COMINO<\/strong><\/td><td>RVO<\/td><td>Met primary endpoint of non-inferiority in best-corrected visual acuity at week 24<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The global development program enrolled over <strong>3,600 patients<\/strong> across multiple continents, establishing Vabysmo\u2019s safety profile and efficacy across diverse retinal disease populations.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Ophthalmology Market:<\/strong> Valued at <strong>$1.2 billion in 2025<\/strong>, projected to grow at <strong>15% CAGR<\/strong> through 2030, driven by aging demographics and rising diabetes prevalence<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Vabysmo\u2019s dual-pathway approach differentiates it from established anti-VEGF monotherapies (e.g., Lucentis, Eylea) by potentially offering longer durability<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> With <strong>CHF 480 million ($530 million)<\/strong> in global sales during H1 2026, China represents a significant growth vector for Roche\u2019s ophthalmology franchise<\/li>\n\n\n\n<li><strong>Commercial Strategy:<\/strong> Roche plans to leverage its established hospital and specialty pharmacy network, with pricing and reimbursement negotiations underway for provincial formulary inclusion by early 2027<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, commercial timelines, and market expectations for Vabysmo. Actual results may differ due to risks including market adoption rates, competitive dynamics, and healthcare policy changes in China.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":71528,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[44,940,15,163,939],"class_list":["post-71527","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-ophthalmology","tag-otcmkts-rhhby","tag-product-approvals","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=71527\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=71527\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-03T06:00:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-03T06:00:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion\",\"datePublished\":\"2026-08-03T06:00:02+00:00\",\"dateModified\":\"2026-08-03T06:00:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0301.webp\",\"keywords\":[\"Ophthalmology\",\"OTCMKTS: RHHBY\",\"Product approvals\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71527#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=71527\",\"name\":\"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0301.webp\",\"datePublished\":\"2026-08-03T06:00:02+00:00\",\"dateModified\":\"2026-08-03T06:00:03+00:00\",\"description\":\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=71527\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0301.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/0301.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=71527#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=71527","og_locale":"en_US","og_type":"article","og_title":"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion","og_description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).","og_url":"https:\/\/flcube.com\/?p=71527","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-03T06:00:02+00:00","article_modified_time":"2026-08-03T06:00:03+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=71527#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=71527"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion","datePublished":"2026-08-03T06:00:02+00:00","dateModified":"2026-08-03T06:00:03+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=71527"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=71527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","keywords":["Ophthalmology","OTCMKTS: RHHBY","Product approvals","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=71527#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=71527","url":"https:\/\/flcube.com\/?p=71527","name":"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=71527#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=71527#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","datePublished":"2026-08-03T06:00:02+00:00","dateModified":"2026-08-03T06:00:03+00:00","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that China\u2019s National Medical Products Administration (NMPA) has granted formal approval for the single-dose pre-filled syringe formulation of Vabysmo (faricimab) to treat neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=71527#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=71527"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=71527#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","width":1080,"height":608,"caption":"Roche's Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=71527#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s Vabysmo Wins NMPA Approval for Retinal Diseases in China Market Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/0301.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=71527"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71527\/revisions"}],"predecessor-version":[{"id":71529,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/71527\/revisions\/71529"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/71528"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=71527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=71527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=71527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}